Semaglutide and tirzepatide are both effective prescription medications used in obesity and metabolic care, but they work differently. Semaglutide targets the GLP-1 receptor; tirzepatide targets both the GIP and GLP-1 receptors. In the first major head-to-head obesity trial, tirzepatide produced greater average weight loss, but that does not automatically make it the right medication for every person.
The practical decision usually comes down to five things: expected weight loss, side effects, appetite response, your medical history, and access. This article walks through each, using the head-to-head evidence rather than anecdotes.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Drug class | GLP-1 receptor agonist | GIP/GLP-1 receptor agonist |
| Weight-loss brand | Wegovy | Zepbound |
| Diabetes brand | Ozempic | Mounjaro |
| Dosing | Weekly injection; oral semaglutide formulations also exist for certain indications | Weekly injection |
| Average weight loss | Strong | Greater on average in head-to-head trial |
| Common side effects | Mostly gastrointestinal | Mostly gastrointestinal |
| Best choice | Depends on the patient | Depends on the patient |
Brands are FDA-approved products. Semaglutide is available in injectable and oral forms, and a higher-dose Wegovy injection (Wegovy HD) was approved in March 2026.
What is the difference between semaglutide and tirzepatide?
Semaglutide targets GLP-1
Semaglutide is a GLP-1 receptor agonist. It increases glucose-dependent insulin secretion, reduces appetite, increases the feeling of fullness, and slows how quickly the stomach empties. Those combined effects can reduce food intake over time. Semaglutide does not "burn fat" directly.
Tirzepatide targets GIP and GLP-1
Tirzepatide is a dual receptor agonist: it acts on both the GIP and the GLP-1 pathways. It affects appetite, satiety, and glucose regulation through those two mechanisms rather than one. This dual action is the fundamental difference between the two medications, and it is the leading explanation for the difference seen in head-to-head data.
Which causes more weight loss: semaglutide or tirzepatide?
On average, tirzepatide, and now there is real randomized evidence rather than guesswork. In SURMOUNT-5, a 72-week head-to-head trial of 751 adults with obesity (without type 2 diabetes), both medications were used at their highest tolerated maintenance doses. The results:
- Average body-weight reduction was 20.2% with tirzepatide versus 13.7% with semaglutide at 72 weeks, a statistically significant difference.
- Tirzepatide also produced greater waist-circumference reduction.
- More people on tirzepatide reached every weight-loss milestone (at least 10%, 15%, 20%, and 25% of body weight).
Which works better for weight loss? On average, tirzepatide. In the SURMOUNT-5 head-to-head trial it produced significantly greater weight loss than semaglutide over 72 weeks. Individual results still vary, an average from a trial is not a prediction for one person.
That last point matters more than the headline number. These are population averages. They tell you which medication tends to produce more weight loss across a group, not which one will work best for you specifically.
Does tirzepatide work faster than semaglutide?
Not necessarily for every person. Tirzepatide produced greater weight reduction over the full 72-week trial, but that is not the same as saying everyone loses weight faster from week one. Both medications are titrated up gradually over months, and early response varies a lot between individuals.
Two slow weeks do not tell you which medication will work better for you long term. It is easy to start a medication, see little movement early, and assume you chose the "wrong" one, but these treatments are designed to work gradually over months.
Which is better for appetite and "food noise"?
"Food noise", the constant mental preoccupation with food, is one of the most common things people compare, and both medications can reduce it. Many patients describe fewer cravings and less food preoccupation on either drug. But here is the honest limit: subjective appetite and "food noise" are far less standardized in clinical trials than weight-loss numbers, so there is not the same strong head-to-head evidence for it as there is for weight.
And a higher average weight-loss result does not guarantee stronger appetite suppression for any given individual. Some people report better appetite control on semaglutide; others on tirzepatide. This is genuinely individual.
Which has fewer side effects?
Both medications most commonly cause gastrointestinal effects: nausea, vomiting, diarrhea, constipation, and abdominal discomfort, which is why doses are increased slowly. In the SURMOUNT-5 trial, these effects were common with both and were mostly mild to moderate during dose escalation. Tirzepatide was not less tolerable overall and had somewhat fewer gastrointestinal adverse effects in that study, but individual tolerance varies widely, so it is not accurate to say one drug simply "has fewer side effects" than the other. The medication you tolerate best is partly an individual matter that only shows up once you start.
Does one cause more muscle loss?
Any substantial weight loss can include some loss of lean mass, regardless of which medication is used. There is not enough head-to-head body-composition evidence to conclude that one consistently causes more lean-mass loss than the other. The practical goal is the same either way: protect muscle with adequate protein, resistance training, and a sensible rate of weight loss. This is one reason weight-loss medication works best inside a plan that includes coaching and training, not on its own.
Semaglutide vs tirzepatide for blood sugar
Both medications also improve blood-sugar regulation, which is why each has a separate brand approved for type 2 diabetes (Ozempic for semaglutide, Mounjaro for tirzepatide). Tirzepatide's dual GIP/GLP-1 action can produce strong glycemic effects. For the purposes of this article the focus is weight, but it is worth knowing the same molecules do double duty in diabetes care under different brand names.
Wegovy vs Ozempic and Zepbound vs Mounjaro
This is where a lot of confusion lives, people mix up the molecule with the brand. It is simpler than it looks:
| Molecule | Weight-management brand | Type 2 diabetes brand |
|---|---|---|
| Semaglutide | Wegovy | Ozempic |
| Tirzepatide | Zepbound | Mounjaro |
The key point: the same active molecule does not mean an identical approved indication, dose, or prescribing context. Wegovy and Ozempic are both semaglutide, but they are approved and dosed for different purposes.
Why would a provider choose semaglutide instead of tirzepatide?
Plenty of reasons, and this is the important counterweight to "tirzepatide wins on average, so semaglutide is obsolete." A provider might favor semaglutide when:
- You are already responding well to it.
- You tolerate it better than the alternative.
- Your prior treatment history points that way.
- There are specific clinical considerations or contraindications.
- Insurance, cost, or access favor it.
- You prefer a particular formulation.
- One of semaglutide's specific FDA-approved indications is particularly relevant to your situation.
Why would a provider choose tirzepatide?
- Greater expected average weight loss is a priority.
- Response to semaglutide has been inadequate.
- You plateaued after an appropriate trial of semaglutide.
- You tolerate tirzepatide better.
- Glucose-management considerations.
- Access and coverage allow it.
Even here, a population-level efficacy advantage is one factor in the decision, not the entire decision.
Can some people do better on semaglutide?
Yes, and this may be the single most important sentence on the page. Clinical trials tell us what happens on average. They do not predict exactly how one person will respond. A medication with lower average weight loss can still be the better medication for an individual who responds well to it, tolerates it, and can actually stay on it long term. "Best on average" and "best for you" are not the same question.
Can you switch from semaglutide to tirzepatide?
Yes, with provider supervision. People switch for reasons like inadequate weight loss after a fair trial, a plateau, intolerable side effects, or a change in cost or coverage. What matters is how it is done: there is no universal milligram-for-milligram conversion between them, because they are different drugs. A switch should be planned by the prescriber, not improvised.
Can you alternate semaglutide and tirzepatide?
No. These medications are not meant to be alternated week to week as a do-it-yourself strategy. Do not combine or alternate them unless a prescribing clinician has given you a specific, medically appropriate transition plan.
Which is safer?
Both have FDA-reviewed safety profiles for their approved uses, and both carry important contraindications and warnings. "Safer" depends on the patient's medical history and how they tolerate the medication. Neither drug is universally safer for everyone. The most common issues for both are the gastrointestinal effects already described, and the specific contraindications are exactly what a prescribing evaluation is for.
What about cost and insurance?
In the real world, cost and coverage often decide the choice as much as the clinical comparison does. Coverage varies dramatically between plans, weight-loss coverage frequently differs from diabetes coverage, prior authorization may apply, and manufacturer and self-pay pricing change over time. It is also worth knowing that compounded versions of these medications were not part of the head-to-head trial and are not FDA-approved. Because EliteRx is a direct-pay clinic, the cost of care is explained to you up front, and a provider can talk through which approved option fits your situation and budget.